Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
Australia
DRUG PRODUCT COMPOSITIONS0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (s)-1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-3-pyrrolidineacetamide
2. Darifenacin
3. Darifenacin Hydrochloride
4. Darifenacine
5. Darifenicin
6. Emselex
7. Enablex
8. Uk-88525
1. Darifenacin Hbr
2. 133099-07-7
3. Emselex
4. Darifenacin (hydrobromide)
5. Darifenacin Hydrobromide [usan]
6. Cr02eyq8gv
7. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide Hydrobromide
8. Uk-88525-04 (hydrobromide)
9. Chebi:31455
10. Uk-88525-04 (hbr)
11. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide Hydrobromide
12. 133099-07-7 (hbr)
13. Dsstox_cid_26780
14. Dsstox_rid_81899
15. Dsstox_gsid_46780
16. (s)-2-{1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl}-2,2-diphenylacetamide Hydrobromide
17. Uk-88525
18. Darilong
19. 2-[(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-diphenylacetamide;hydrobromide
20. Uk 88525-04 Hydrobromide
21. Cas-133099-07-7
22. Ncgc00168775-01
23. Unii-cr02eyq8gv
24. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hydrobromide
25. 2-{(3s)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl}-2,2-diphenylacetamide Hydrobromide
26. Enablex (tn)
27. Darifenacinhydrobromide
28. Diphenyl-acetamide Hydrobromide
29. Darifenacin Hydrobromide- Bio-x
30. Chembl1200935
31. Dtxsid9046780
32. Hy-a0012
33. Tox21_112636
34. Darifenacin Hydrobromide (jan/usan)
35. Darifenacin Hydrobromide [mi]
36. Mfcd08141803
37. S3144
38. Darifenacin Hydrobromide [jan]
39. Akos015969311
40. Tox21_112636_1
41. Ac-1894
42. Ccg-220969
43. Cs-0380
44. Darifenacin Hydrobromide [mart.]
45. Darifenacin Hydrobromide [usp-rs]
46. Darifenacin Hydrobromide [who-dd]
47. Ncgc00263922-02
48. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (3s)-
49. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-alpha,alpha-diphenyl-, Monohydrobromide, (s)-
50. 3-pyrrolidineacetamide, 1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-alpha,alpha-diphenyl-, Hydrobromide (1:1), (3s)-
51. As-35087
52. Bd164350
53. Darifenacin Hydrobromide [ema Epar]
54. Darifenacin Hydrobromide, >=98% (hplc)
55. Sw219426-1
56. Darifenacin Hydrobromide [orange Book]
57. Uk-88525-04
58. D01699
59. Q-101006
60. Q27114313
61. Z1691545283
62. Darifenacin Hydrobromide, United States Pharmacopeia (usp) Reference Standard
63. (s)-2-(1-(2-(2,3-dihydrobenzofuran-5-yl)ethyl)-3-pyrrolidnyl)-2,2-diphenylacetamide Hbr
64. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohbr, (3s)-
65. 3-pyrrolidineacetamide, 1-(2-(2,3-dihydro-5-benzofuranyl)ethyl)-.alpha.,.alpha.-diphenyl-, Monohydrobromide, (3s)-
| Molecular Weight | 507.5 g/mol |
|---|---|
| Molecular Formula | C28H31BrN2O2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 7 |
| Exact Mass | 506.15689 g/mol |
| Monoisotopic Mass | 506.15689 g/mol |
| Topological Polar Surface Area | 55.6 Ų |
| Heavy Atom Count | 33 |
| Formal Charge | 0 |
| Complexity | 607 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 4 | |
|---|---|
| Drug Name | Darifenacin hydrobromide |
| Active Ingredient | Darifenacin hydrobromide |
| Dosage Form | Tablet, extended release |
| Route | oral |
| Strength | 7.5mg; 15mg |
| Market Status | Tentative Approval |
| Company | Anchen Pharms |
| 2 of 4 | |
|---|---|
| Drug Name | Enablex |
| PubMed Health | Darifenacin (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
| Active Ingredient | Darifenacin hydrobromide |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | eq 15mg base; eq 7.5mg base |
| Market Status | Prescription |
| Company | Warner Chilcott |
| 3 of 4 | |
|---|---|
| Drug Name | Darifenacin hydrobromide |
| Active Ingredient | Darifenacin hydrobromide |
| Dosage Form | Tablet, extended release |
| Route | oral |
| Strength | 7.5mg; 15mg |
| Market Status | Tentative Approval |
| Company | Anchen Pharms |
| 4 of 4 | |
|---|---|
| Drug Name | Enablex |
| PubMed Health | Darifenacin (By mouth) |
| Drug Classes | Urinary Antispasmodic |
| Drug Label | ENABLEX (darifenacin) is an extended-release tablet which contains 7.5mg or 15mg darifenacin as its hydrobromide salt. The active moiety, darifenacin, is a potent muscarinic receptor antagonist.Chemically, darifenacin hydrobromide is (S)-2-{1-[... |
| Active Ingredient | Darifenacin hydrobromide |
| Dosage Form | Tablet, extended release |
| Route | Oral |
| Strength | eq 15mg base; eq 7.5mg base |
| Market Status | Prescription |
| Company | Warner Chilcott |
Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome.
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Urological Agents
Drugs used in the treatment of urological conditions and diseases such as URINARY INCONTINENCE and URINARY TRACT INFECTIONS. (See all compounds classified as Urological Agents.)
G04BD10
API SUPPLIERS
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
HRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.
Megafine Pharma is engaged in the production of APIs, and advanced intermediates, and offers contract manufacturing services.
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-23
Pay. Date : 2013-03-20
DMF Number : 26533
Submission : 2012-09-30
Status : Active
Type : II
Date of Issue : 2022-07-27
Valid Till : 2025-07-21
Written Confirmation Number : WC-0087-(Annexure-1)
Address of the Firm : Plot No.1 to 5, 31 to 35 & 48 to 51, 26 & K/201, Village Lakhmapur, Taluka Dindori, Dist. Nashik-422 202, Maharashtra
| Available Reg Filing : ASMF, BR |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22184
Submission : 2008-11-17
Status : Active
Type : II
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm : Plot No. 3109, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat
NDC Package Code : 66039-861
Start Marketing Date : 2008-11-17
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-28
Pay. Date : 2013-08-14
DMF Number : 22206
Submission : 2008-11-21
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-06-03
Pay. Date : 2012-12-11
DMF Number : 22225
Submission : 2008-11-21
Status : Active
Type : II
Date of Issue : 2019-08-16
Valid Till : 2025-08-15
Written Confirmation Number : WC-0022
Address of the Firm :
NDC Package Code : 50370-0007
Start Marketing Date : 2010-04-15
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-15
Pay. Date : 2013-09-23
DMF Number : 27047
Submission : 2013-09-16
Status : Active
Type : II
Date of Issue : 2019-11-28
Valid Till : 2022-07-02
Written Confirmation Number : WC-0079
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-08-21
Pay. Date : 2012-12-06
DMF Number : 25530
Submission : 2011-12-08
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23269
Submission : 2009-11-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26419
Submission : 2012-09-27
Status : Inactive
Type : II
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 1...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 21513
DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 7...DOSAGE - TABLET, EXTENDED RELEASE;ORAL - EQ 7.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
USFDA APPLICATION NUMBER - 21513
Related Excipient Companies
SPI Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seqens
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Boai NKY Pharmaceuticals Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nanjing Well Pharmaceutical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ACG Worldwide
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Actylis
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Aeon Procare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Anhui Sunhere Pharmaceutical Excipients Co.,Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Avesta Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Clariant
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Corel Pharma Chem
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DFE Pharma
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Finar
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Gangwal Chemicals
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ideal Cures Pvt Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kerry
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Kima Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Lonza Capsugel
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Microlex e.U
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Nomisma Healthcare
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Novo Excipients
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pharmatrans-Sanaq
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Pluviaendo
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Prachin Chemical
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qianhao Chemical (Hebei) Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Qualicaps
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Roquette
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Seppic
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Shenmei Pharmaceutical Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Shanghai Welltone Material Technology Co., Ltd
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Sigachi Industries
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]The Dow Chemical Company
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Ulanqab Kema New Material
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Excipients by Applications
Coating Systems & Additives
Fillers, Diluents & Binders
Controlled & Modified Release
Direct Compression
Thickeners and Stabilizers
Lubricants & Glidants
Topical
Co-Processed Excipients
Film Formers & Plasticizers
Granulation
Solubilizers
Parenteral
Disintegrants & Superdisintegrants
API Stability Enhancers
Empty Capsules
Emulsifying Agents
Vegetarian Capsules
Taste Masking
Coloring Agents
Chewable & Orodispersible Aids
Rheology Modifiers
Surfactant & Foaming Agents
Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
USP
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
